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Background. Although the human leukocyte antigen (HLA)–B*5701 is highly associated with a hypersensitivity
reaction (HSR) to abacavir (ABC), variable sensitivities have been reported when clinical data alone have been
used to deﬁne an ABC HSR. This study evaluated the sensitivity of detection of the HLA-B*5701 allele as a marker
of ABC HSRs in both white and black patients, using skin patch testing to supplement clinical diagnosis.
Methods. Whiteand black patients,identiﬁedthroughchartreview,wereclassiﬁedashavingreceivedadiagnosis
of an ABC HSR based on clinical ﬁndings only (a clinically suspected ABC HSR) or based on clinical ﬁndings
and a positive skin patch test result (an immunologically conﬁrmed [IC] ABC HSR). Control subjects were racially
matched subjects who tolerated ABC for 12 weeks without experiencing an ABC HSR. Patients and control
subjects were tested for the presence of HLA-B*5701. Sensitivity, speciﬁcity, and odds ratios for the detection of
HLA-B*5701 as a marker for an ABC HSR were calculated for white and black participants.
Results. Forty-two (32.3%) of 130 white patients and 5 (7.2%) of 69 black patients who met the criteria for
clinically suspected HSRs had IC HSRs. All 42 white patients with IC HSRs were HLA-B*5701 positive (sensitivity,
100%; odds ratio, 1945; 95% conﬁdence interval, 110–34,352). Among all white patients with clinically suspected
HSRs, sensitivity was 44% (57 of 130 patients tested positive for HLA-B*5701); speciﬁcity among white control
subjects was 96%. Five of 5 black patients with IC HSRs were HLA-B*5701 positive (sensitivity, 100%; odds ratio,
900; 95% conﬁdence interval, 38–21,045). Among black patients with clinically suspected HSRs, the sensitivity
was 14% (10 of 69 tested positive for HLA-B*5701); speciﬁcity among black control subjects was 99%.
Conclusions. Although IC ABC HSRs are uncommon in black persons, the 100% sensitivity of HLA-B*5701
as a marker for IC ABC HSRs in both US white and black patients suggests similar implications of the association
between HLA-B*5701 positivity and risk of ABC HSRs in both races.
The nucleoside reverse-transcriptase inhibitor,abacavir
sulfate (ABC), is an effective antiretroviral drug with
excellent long-term safety. The major treatment-limi-
ting toxicity of ABC is a hypersensitivity reaction
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(HSR), which occurs in ∼5% of patients [1]. ABCHSRs
are typicallyassociatedwithacombinationof2symp-
toms, including generalized malaise, rash, fever, and/or
gastrointestinal symptoms. All symptoms typically re-
solve within several days after discontinuation of ABC
therapy but recur more quickly and severely upon re-
challenge with the drug. Permanent discontinuation of
ABC therapy is mandated for any patient who receives
a diagnosis of an HSR.
Although the exact mechanism of ABC HSRs is un-
known, an immunogenetic basis is likely (supported by
laboratory studies [2] and the rapid and severe re-
challenge reactions). Early reports that noted familial1112 • CID 2008:46 (1 April) • HIV/AIDS
susceptibility and decreased frequency of ABC HSRs in certain
racial groups suggested a genetic basis for the reaction [1, 3].
A strong association has been consistently reported between
the HLA-B*5701 allele and ABC HSRs [4–6]. However, studies
have shown variable sensitivity of detection of the HLA-B*5701
allele as a marker for HSRs, with much highersensitivityamong
white populations than among other racial or ethnic groups.
Black populations show lower carriage rates of HLA-B*5701
[5, 7] and a lower incidence of ABC HSRs [1, 8].
Initial studies that evaluated the sensitivity of HLA-B*5701
as a marker for ABC HSRs were based on clinical diagnosis.
The overlapping nature of ABC HSR symptoms with the ad-
verse events associated with concurrent antiretroviral therapy
(such as efavirenz) and with symptoms of infection and im-
mune restoration disease have confounded accurate clinical di-
agnosis [1, 9]. In blinded clinical trials, rates of suspected ABC
HSRs among subjects not receiving ABC therapy have varied
from 2% to 7% [10–14]. Because correct identiﬁcation of phe-
notype is critical to accurately estimate sensitivity, previousret-
rospective studies that used clinical diagnosis alone to detect
the phenotype involved in cases of ABC HSRs have shown low
sensitivity HLA-B*5701 screening, particularlyamongblackpa-
tients; this is likely because of the overshadowing of immu-
nologically mediated HSRs by false-positive clinical diagnoses.
Skin patch testing has been used successfully as an adjunct
to clinical diagnosis to identify patients with immunologically
mediated ABC HSRs. These studies have shown a consistently
high sensitivity of HLA-B*5701 among patients with a history
of ABC HSRs conﬁrmed with skin patch testing but were lim-
ited to a primarily white population [2, 15–17]. The aim of
the present study (ABC107442/SHAPE) was to assess the sen-
sitivity of HLA-B*5701 as a marker for clinically diagnosedand
patch test–conﬁrmed ABC HSRs in black and white patients
in the United States.
METHODS
Study design and population. The Study of Hypersensitivity
to Abacavir and Pharmacogenetic Evaluation (SHAPE) study
was a retrospective case-control study to evaluate the sensitivity
and speciﬁcity of the HLA-B*5701 allele as a marker for ABC
HSRs in the black and white populations in the United States
(study ABC107442; clinical trials identiﬁer, NCT00373945).
Approvals to conduct this study were obtained from a cen-
tralized institutional review board and, where required, from
individual site institutional review boards.
Participants were assessedforeligibilitythroughretrospective
assessment of information regarding clinical presentation of
ABC HSR symptoms, antiretroviral therapy, and date of use of
ABC-containing products. Participants were eligible for the
study if they were self-identiﬁed as either black or white, pro-
vided written informed consentforstudyprocedures(including
pharmacogenetic research), and had experienced clinically sus-
pected (CS) ABC HSRs consisting of at least 2 major symptoms
(fever, rash, or gastrointestinal or constitutional symptoms)
with onset date within 6 weeks after initiating ABC therapy.
The group of black participants included all of those who iden-
tiﬁed themselves as “black” and was not restricted to those who
were of African American or African descent.
All participantsunderwentskinpatchtestingandhadablood
sample obtained for pharmacogenetic research. The2 following
case deﬁnitions were used in this study: a CS ABC HSR was
deﬁned as diagnosis of an ABC HSR based on clinical ﬁndings
only, and an immunologically conﬁrmed (IC) ABC HSR was
deﬁned as diagnosis of an ABC HSR based on clinical ﬁndings
and a positive skin patch test result.
Racially matched control subjects were retrospectively iden-
tiﬁed from subjects who had taken ABC for at least 12 weeks
while participating in a previous clinical study, had not expe-
rienced ABC HSRs, had provided written informed consent,
and had a blood sample obtainedforpharmacogeneticresearch.
Data were analyzed separately for white and black patients be-
cause of the differential sensitivities of HLA-B*5701 screening
among white and black patients with ABC HSRs (48% and
8%, respectively) [5].
Skin patch testing. Skin patch tests were prepared and ap-
plied in duplicate according to the procedure previously re-
ported by Phillips et al. [15] and were adapted to use 1% and
10% concentrations of ABC and excipient and petrolatumcon-
trols. Skin patch testing consisted of applying diluted, nonir-
ritating concentrations of ABC to the surface of the skin of
participants who were suspected to have experienced an ABC
HSR. A positive cutaneous reaction (erythema, induration,
pruritis, and in some cases, vesiculation and blistering)implied
immunological conﬁrmation of the original ABC HSR. Patch
test kits were standardized, with detailed instruction regarding
application and interpretation of the test beingdistributedfrom
a central site. Test results were read and recorded at 24 and 48
h after application, and photographic images were collected
using standard cameras (Kodak EasyShare C530). Statistical
analyses were based on patch test results, as determined by site
investigators (ﬁgure 1).
Pharmacogenetic evaluation. Blood samples were ob-
tained from all participantsforHLA-B*5701detectionandwere
assayed for the presence of HLA-B*5701 using high-resolution
DNA-based assay methodologies (Quest Diagnostics).
Statistical analyses. The sample size target of 40 patients
with IC HSRs for each race was based on feasibility of recruit-
ment and acceptable precision around the observed point es-
timate. Using the sample size software package PASS 2005
(NCSS), a sample size of 40 patients with IC HSRs produced
a 95% CI with 0.15 precision (one-half of the width of the
conﬁdence interval), assuming an observed sensitivity of 0.60.HIV/AIDS • CID 2008:46 (1 April) • 1113
Figure 1. Positive skin patch test results photographed 48 h after patch application for a white patient (left) and a black patient (right). In each
image, the patch on the left was removed 24 h after application and the patch on the right was removed 48 h after application.
A sample size comprising 80 control subjects would produce
a 95% CI with 0.07 precision, assuming an observed speciﬁcity
of 0.90. Because of the very low carriage frequency of HLA-
B*5701 among control subjects, attempts were made to locate
up to 200 control subjects for estimating the speciﬁcityofHLA-
B*5701. Assuming an OR of 5 and the sample sizes proposed
for this study, there would be sufﬁcient power (190%) to test
the association of HLA-B*5701 with ABC HSRs amongpatients
and control subjects ( ). The primary objective of this a p 0.05
study was to estimate the sensitivity of HLA-B*5701 in white
and black patients with IC HSRs. In addition, sensitivities for
determination of CS HSRs among white and black patientsand
speciﬁcities among white and black control subjects were cal-
culated. ORs and exact x
2 tests were used to evaluate the as-
sociation between the presence of HLA-B*5701 and ABCHSRs.
To estimate the ORs and 95% CIs when 1 of the cells contained
zero subjects, 0.5 was added to each of the cells before com-
puting [18].
Statistical analyses included all enrolled subjects for whom
HLA-B*5701 screening and skin patch testingresultswereavail-
able. A per-protocol analysis was also conducted to exclude
subjects who violated any major study criterion. The full anal-
ysis results, which closely matched the per-protocol results, are
presented. Statistical analyses were conducted using SAS, ver-
sion 8.2 (SAS Institute).
RESULTS
We identiﬁed 130 white patients with CS HSRs, 42 (32%) of
whom had a positive skin patch test result. Of 69 black patients
with CS HSRs, 5 (7%) had a positive skin patch test result. For
4 patients (3 white and 1 black), valid skin patch test results
were not available, generally because the patches did not adhere
to the skin, despite attempts at reapplication and change in
application site. These patients were excluded from theprimary
analysis, because it was not possible to classify them as having
positive or negative skin patch test results. They were included
in the CS HSR analysis but wereexcludedfromtheper-protocol
analysis. Baseline characteristics, including details of the qual-
ifying ABC HSR event, are described in tables 1 and 2. De-
mographic characteristics were similar for white patients and
control subjects and for black patients and control subjects.
All of the white patients with IC HSRs experienced onset of
ABC HSR symptoms within 17 days after starting ABC therapy,
and black patients with IC HSRs experienced onset of symp-
toms within 32 days after initiation of ABC therapy. The ma-
jority of patients with IC HSRs (90% of white patients and
100% of black patients) presented with ABC HSR symptoms
in 3 categories (table 2). Fever and gastrointestinalsymptoms
were the most commonly reported symptoms in white and
black patients with IC HSRs, respectively.
The patterns of association between HLA-B*5701 and ABC
HSRs are presented in table 3. All of the white patients with
IC HSRs were HLA-B*5701 positive(sensitivity,100%).Among
all white patients with CS HSRs, the sensitivity of HLA-B*5701
was 44%. Fifteen white patients with CS HSRs and negative
skin patch test results and 8 white control subjects also were
HLA-B*5701 positive. The corresponding sensitivities among
black patients were 100% for patients with IC HSRs and 14%
for patients with CS HSRs. Five black patients with CS HSRs
and negative skin patch test results and 2 black control subjects
were HLA-B*5701 positive. The speciﬁcities of HLA-B*5701
among white and black patients were 96% and 99%, respec-
tively. As indicated by ORs and their 95% CIs (OR for white
patients, 1945 [95% CI, 110–34352]; OR for black patients,900
[95% CI, 38–21045]), the presence of HLA-B*5701 is signiﬁ-
cantly associated with ABC HSRs, regardless of race and case
deﬁnition of ABC HSR. The strongest associations were ob-
served in patients with IC HSRs.
There were no serious adverse events that were associated
with study procedures, including skin patch testing. Most of1114 • CID 2008:46 (1 April) • HIV/AIDS
Table 1. Demographic and baseline characteristics of the study population.
Characteristic
White participants Black participants
































Age, mean years (range) 44 (23–57) 45 (22–73) 45 (22–73) 41 (19–72) 47 (32–57) 45 (22–76) 45 (22–76) 41 (19–73)
Male sex, % 90 76 82 93 100 57 59 71
NOTE. ABC, abacavir; CS, clinically suspected; HSR, hypersensitivity.
a Among patients with CS ABC HSR, 3 white patients and 1 black patient did not have valid skin patch test results. Therefore, the sum of patients who
had positive skin patch test results and patients who had negative skin patch test results is not equal to the total number of patients with CS ABC HSR.
the adverse events noted were cutaneous and mild to moderate
in severity. A few participants (4 white participants and 5 black
participants) reported transient and self-limited constitutional
symptoms, such as nausea, fatigue, and myalgias, that were
attributed by the site investigator to topical ABC therapy. None
of these patients had the patch testing procedure interrupted
or discontinued.
DISCUSSION
In this analysis, the sensitivity estimate of HLA-B*5701 as a
marker for IC HSRs was 100% for both white and black pa-
tients. These results contrast with the lower sensitivities, par-
ticularly among black patients, in previous studies that used
only a clinical diagnosis to deﬁne an ABC HSR (ﬁgure 2).
Among patients with CS HSRs, the sensitivities of HLA-B*5701
among white patients (44%) and black patients (14%) were
similar to those reportedelsewhere[5].Theassociationbetween
IC HSRs and the presence of the HLA-B*5701 allele is striking
and further establishes this genetic marker as a potential pre-
dictor of an ABC HSR in a clinical context.
Past studies have yielded a range of estimates for the sen-
sitivity of HLA-B*5701 as a predictor of an ABC HSR. One of
the possible explanations for the variability in ﬁndings is the
clinical criteria used in diagnosing ABC HSRs. The frequent
concomitant use of efavirenz, which can result in rash and
constitutional symptoms early during the course of therapy,
likely has increased the reporting of CS HSRs. Historical evi-
dence supports this thesis. Before the more widespread use of
efavirenz as part of a potent 3-drug regimen, the initial studies
of ABC therapy reported HSR rates of 2%–3% [19].Incontrast,
in more recent studies in which ABC therapy has been used
in conjunction with efavirenz, the incidence of CS HSRs was
7%–9%, suggesting confounding of the clinical presentation of
ABC HSRs. Supporting this notion is the 2%–7% rates of ABC
HSRs that have been reported consistently in the non–ABC
therapy arms in randomized, double-blinded, controlled stud-
ies [10–14].
Similar to our study, other studies that have used skin patch
testing to supplement a clinical diagnosis of an ABC HSR have
also observed 100% sensitivity of HLA-B*5701 as a marker for
IC HSRs [2, 16, 17]. Furthermore, reports have indicated that
prospective screening to exclude patients who are HLA-B*5701
positive from receiving ABC therapy results in a decrease in
the incidence of ABC HSRs [20–22].
Although patch testing accurately identiﬁes patients who
have immunologically mediated ABC HSRs, clinical manage-
ment accurately identiﬁes individuals who have not developed
symptoms of an HSR and, thus, are tolerant of ABC. Therefore,
the best estimates of sensitivity of HLA-B*5701 screening for
ABC HSRs are provided by patch testing (IC HSRs), and the
estimated speciﬁcities are provided by clinical evaluationalone.
Assuming a 2% carriage frequency of HLA-B*5701 among US
black persons and the 100% sensitivity and 99% speciﬁcity of
HLA-B*5701 observed in the present study, the estimated pos-
itive predictive value of screening would be ∼50%, and the
negative predictive value would be 100%. To illustrate this phe-
nomenon, if a similar population of 100 US black persons was
screened, we would expect that 98 persons would be identiﬁed
as HLA-B*5701 negative and could conﬁdently initiate ABC
therapy with very low risk of developing a HSR. Avoidance of
ABC therapy for the 2 HLA-B*5701–positive patients would
be expected to prevent 1 case of an ABC HSR and would
inappropriately deny ABC therapy to 1 patient who would have
tolerated the drug. Although this implies that 100 patients
would need to be screened to prevent 1caseofimmunologically
mediated HSRs, it must be borne in mind that 2%–7% of
patients have ABC therapy inappropriately stopped because of
clinical overdiagnosis of HSRs [10–14], and open genetic
screening has been shown to substantially reduce this endpoint
[20–22].
From the perspective of an individual patient, screening re-
duces the potential anxiety associated with starting ABC ther-
apy. This practice would avoid exposing and sensitizing HLA-
B*5701–positive patients to ABC and would facilitate the more
accurate diagnosis based on any symptoms that may arise in
an HLA-B*5701–negative individual during the ﬁrst few weeksHIV/AIDS • CID 2008:46 (1 April) • 1115
Table 2. Description of symptoms for the qualifying abacavir (ABC) hypersensitivity (HSR) event.
Characteristic

























Time from initiation of ABC therapy to
onset of symptoms,
b days
0–21 42 (100) 61 (80) 106 (88) 4 (80) 44 (77) 49 (78)
22–42 0 (0) 9 (12) 9 (7) 1 (20) 7 (12) 8 (13)
142
c 0 (0) 6 (8) 6 (5) 0 (0) 6 (11) 6 (10)
Median (range) 7 (0–17) 6 (0–291) 6 (0–291) 7 (7–32) 8 (0–469) 7 (0–469)
No. of categories of symptoms
d
None and/or missing 0 (0) 3 (4) 3 (2) 0 (0) 2 (3) 2 (3)
1 0 (0) 1 (1) 1 (!1) 0 (0) 3 (5) 4 (6)
2 4 (10) 24 (28) 30 (23) 0 (0) 23 (37) 23 (33)
3 38 (90) 57 (67) 96 (74) 5 (100) 35 (56) 40 (58)
Symptom category
Fever 41 (98) 53 (61) 94 (72) 4 (80) 34 (54) 38 (55)
Rash 27 (64) 51 (60) 78 (60) 3 (60) 30 (48) 34 (49)
Gastrointestinal 25 (60) 55 (65) 83 (64) 5 (100) 43 (68) 48 (70)
Constitutional 39 (93) 65 (76) 107 (82) 4 (80) 43 (68) 47 (68)
Respiratory 13 (31) 26 (31) 40 (31) 1 (20) 11 (17) 12 (17)
Time from diagnosis of HSR to study entry,
median days (range) 763 (7–3133) 1326 (8–3550) 1012 (7–3550) 263 (56–2313) 1845 (28–2761) 1718 (28–2761)
NOTE. Data are no. (%) of patients, unless otherwise indicated. CS, clinically suspected.
a Among patients with CS ABC HSR, 3 white patients and 1 black patient did not have valid skin patch test results. Therefore, the sum of patients who
had positive skin patch test results and patients who had negative skin patch test results is not equal to the total number of patients with CS ABC HSR.
b Data are for 42 white patients with positive skin patch test results, 76 white patients with negative skin patch test results, 121 white patients with
CS cases, 5 black patients with positive skin patch test results, 57 black patients with negative skin patch test results, and 63 black patients with CS
cases.
c Patients who experienced onset of ABC HSR 16 weeks after initiating ABC therapy were considered to be protocol violators.
d Symptom categories included fever, rash, gastrointestinal symptoms, and constitutional symptoms. Patients with missing and/or no symptoms either
did not have documented evidence of ABC HSR or had symptoms that could not be placed in any of the 4 symptom categories; patients with only 1
symptom were considered to be protocol violators.
of antiretroviral therapy. From the clinician’s point of view, it
is the ease, level of reimbursement, availability,andturnaround
time of accurate testing that also determine the local cost-
beneﬁt ratio and uptake of testing. Once testing is introduced,
it will be difﬁcult to deny access to screening on the basis of
self- or clinician-identiﬁed race. Therefore, considerationofthe
balance between number of patients tested and the total num-
ber of prevented cases of HSRs is of less relevance to physicians
than it is to those who fund laboratory testing.
Although a positive skin patch test result is a reliable indi-
cator of immunologically mediated HSRs, a negative patch test
result does not completely exclude immunologically mediated
HSRs. Our study identiﬁed 15 white patients and 5 black pa-
tients with CS HSRs who were HLA-B*5701 positive and had
negative skin patch test results. Although some patients may
be HLA-B*5701 positive and ABC tolerant, false-negative skin
patch test results due to host or operator factors cannot be
ruled out in these cases. This lack of perfect analyticalsensitivity
of skin patch testingamongHLA-B*5701–positivepatientswith
CS ABC HSRs indicates that skin patch testing should not be
used as a clinical tool for excluding a HSR diagnosis for pur-
poses of ABC rechallenge.
Despite a large number of participating sites (57 sites) and
extension of the enrollment period, only 69 black participants
met the inclusion criteria for CS HSRs. Of those, only5patients
(7%) had IC HSRs—far fewer than the 40 black patients with
IC HSRs that were planned for this study. Exploring the ro-
bustness of these ﬁndings with only 5 black patients who had
IC ABC HSRs indicates a relatively small probability (33%) of
observing 5 HLA-B*5701–positive patients among 5 patients
with IC HSRs if thetrueprobabilityhadbeen80%.Eventhough
there were only 5 black patients with IC HSRs, the association
between IC HSRs and the presence of HLA-B*5701 was strong
enough that the lower limit of the 95% CI was well above 1.
If only 4 of the 5 black patients with IC HSRs were HLA-
B*5701 positive, the OR would have been 408 (95% CI, 21–
20,123). If only 1 of the 5 black patients with IC HSRs were
HLA-B*5701 positive, the OR would have decreasedto26(95%
CI, 0.3–555). These exploratory results support the robustness
of the original ﬁndings. Even though the number of black1116 • CID 2008:46 (1 April) • HIV/AIDS
Table 3. Results of pharmacogenetic analyses.
Analysis
White participants Black participants



































b 129 202 5 63 69 206
No. of results indicat-
ing presence of
HLA-B*5701 42 (100) 15 (18) 57 (44) 8 (4) 5 (100) 5 (8) 10 (14) 2 (!1)
Sensitivity, % (95% CI) 100 (92–100) … 44 (35–53) NA 100 (48–100) … 14 (7–25) NA
Speciﬁcity, % (95% CI) NA … NA 96 (92–98) NA … NA 99 (97–100)
OR (95% CI) 1945 (110–34,352) … 19 (8–48) Reference 900 (38–21045) … 17 (4–164) Reference
NOTE. ABC, abacavir; CS, clinically suspected; HSR, hypersensitivity; NA, not applicable.
a Among patients with CS ABC HSR, 3 white patients and 1 black patient did not have valid skin patch test results. Therefore, the sum of patients
who had positive skin patch test results and patients who had negative skin patch test results is not equal to the total number of patients with CI ABC
HSR.
b The blood sample obtained from 1 patient was not processed correctly, and a second sample was unattainable; thus, the HLA-B*5701 screening
result was not available for this 1 patient.
Figure 2. Sensitivity of HLA-B*5701 screening as determined by past studies and the Study of Hypersensitivity to Abacavir and Pharmacogenetic
Evaluation (SHAPE) study, in which abacavir (ABC) hypersensitivity (HSR) was deﬁned on the basis of a clinical diagnosis alone, and in only the SHAPE
study, in which ABC HSR was also deﬁned on the basis of immunological conﬁrmation (IC HSR). Numbers in parentheses indicate number of cases
of ABC HSR. CNA30027 and CNA30032 were retrospective case-control studies. Of the 1041 participants included in the CNA30032 study, a random
subset of 541 participants was used for the calculation of sensitivity of HLA-B*5701 screening. Similar to the SHAPE study, patients in the CNA30027
and CNA30032 studies had to have had documented evidence of ABC HSR (consisting of symptoms in 2 categories).
patients was small, the strength of the association between
HLA-B*5701 and IC HSRs (demonstrated by the 100% sen-
sitivity and high OR in the black cohort) suggests that the
association is likely to be generalizable.
Inclusion criteria for the trial were stringent with respect to
timing (occurrence of symptoms !6 weeks after initiation of
ABC therapy) and symptoms (2 categories consistent with
HSRs). Despite the criteria, some participants were enrolled
who did not meet the inclusioncriteria.Becausetheseviolations
were discovered only after monitoring of the site and because
the study period was brief (only 3 days), these participantswere
included in the analysis despite the violation of entry criteria.
It is interesting that none of the 12 patients with symptoms
presenting after 6 weeks and none of the 9 subjects with !2
categories of symptoms had IC HSRs. The criteria established
for entry were based on evaluation of risk factor analyses [1];
the criteria, if observed, can help to differentiate HSRs from
events involving similar symptoms.
Recent observational studies employing screening for HLA-
B*5701 have shown a reduction in the rates of ABC HSRs [20–
22] and all-cause ABC therapy discontinuation, suggestingthat
screening can promote more-informed treatment of patientsHIV/AIDS • CID 2008:46 (1 April) • 1117
[21]. A large prospective study, PREDICT-1, was statistically
powered to determine the association between HLA-B*5701
and ABC HSRs in a white population [23]. Because of the
lower frequency of the allele among black populations (fre-
quency, 2.5%), a powered, prospective study aimed at study-
ing the association between HLA-B*5701 and ABC HSRs in a
black population is not feasible. The retrospective case-control
study design of the SHAPE study allowed us to identify the
strong association between the presence of HLA-B*5701 and
IC ABC HSRs in a black population.
In summary, the SHAPE study complements the results pro-
vided by prospective studies by providing new and critical in-
formation that the HLA-B*5701 allele is important for iden-
tifying persons at highest risk of developing ABC HSRs among
both white and black populations. These ﬁndings, in conjunc-
tion with robust laboratory assay results and quality assurance
programs, have signiﬁcant implications for the use of HLA-
B*5701 screening in clinical settings worldwide, so that preth-
erapy assessment of the presence of the allele could be used to
identify persons who may be at the highest risk of developing
ABC HSRs and to facilitate safer treatment decisions based on
this knowledge [24–27]. Because of the more expanded ex-
perience with adverse drug reactions, such as anemia, neutro-
penia, and mitochondrial toxicities, associated with the alter-
native nucleoside analogues currently in common use in
resource-poor settings, other safe options will be needed [28–
31]. These ﬁndings support the generalizability of HLA-B*5701
screening for the prevention of ABC HSRs in US white and
black populations.
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